The Antioxidant Megadose Myth: Why More Vitamin C and E Is Not Better

The antioxidant supplement category was built on a simple logic: free radicals cause oxidative damage, oxidative damage contributes to disease, so blocking free radicals with megadose antioxidants should prevent disease. This logic dominated supplement marketing from the 1980s through the early 2000s and animated a wave of large randomized trials. Those trials returned a remarkably uniform answer: high-dose antioxidant supplementation either does nothing useful or causes net harm, depending on the population studied. Three decades later, the megadose pitch persists in marketing while the trial evidence pulls in the opposite direction.

What the big cardiovascular and cancer trials showed

The Heart Protection Study randomized 20,536 high-risk adults to a combination of vitamin E 600 mg, vitamin C 250 mg, and beta-carotene 20 mg daily for five years. There was no effect on cardiovascular events, cancer incidence, or all-cause mortality. The Women's Health Study found no benefit of vitamin E 600 IU every other day for ten years on cardiovascular outcomes. SELECT (Selenium and Vitamin E Cancer Prevention Trial) was stopped early when vitamin E 400 IU daily was associated with a 17% relative increase in prostate cancer incidence.

Two beta-carotene trials — CARET and ATBC — were halted early when high-dose beta-carotene supplementation produced statistically significant increases in lung cancer in smokers. A 2007 meta-analysis pooling 68 trials with 232,606 participants reported that antioxidant supplementation (vitamin A, beta-carotene, vitamin E) was associated with a small but statistically significant increase in all-cause mortality. Vitamin C supplementation showed no significant effect; selenium trended modestly favorably.

Why the logic was wrong

Two problems with the original theory. First, reactive oxygen species are not purely pathological. They function as signaling molecules in vascular tone regulation, insulin sensing, training adaptation, immune responses, and cellular stress response activation. Blanket suppression interferes with these processes. The exercise adaptation literature, in particular, shows clearly that high-dose antioxidants taken around training blunt the mitochondrial biogenesis and insulin-sensitivity gains that exercise would otherwise produce.

Second, oxidative damage in dietary epidemiology is associated with foods that contain antioxidants but is not necessarily prevented by the antioxidants themselves. People who eat more fruits and vegetables have lower disease rates; isolating the antioxidant vitamins from the food matrix and giving them in pharmacologic doses does not reproduce the epidemiologic association. This is a recurrent finding across nutrition trials and points to the food matrix — fiber, phytochemicals, food displacement of less healthy options — doing more of the work than the isolated nutrients.

Where antioxidant supplementation does still make sense

Specific deficiency correction remains a legitimate indication: vitamin C in scurvy, vitamin E in fat-malabsorption syndromes or abetalipoproteinemia, selenium in Keshan disease endemic regions. The AREDS and AREDS2 formulations (combinations of vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin) slow age-related macular degeneration progression in intermediate-stage patients — this is a specific disease intervention with positive trial evidence, not a generic antioxidant supplement.

Vitamin C in physiological doses (the 90 mg/day RDA, or up to a few hundred mg from food and modest supplementation) is safe and supports normal physiology. The megadose tradition of 1,000–3,000 mg daily lacks supporting outcome evidence and is associated in some cohort data with increased kidney stone risk in men.

Bottom line

Megadose antioxidant supplementation does not prevent cardiovascular disease, cancer, or all-cause mortality; in several large trials it actively produces harm. Reactive oxygen species are not the villain the 1980s marketing assumed. Correct documented deficiencies, follow disease-specific formulations like AREDS2 where the trial evidence supports them, and otherwise get antioxidants from the foods that contain them rather than from megadose capsules.